External challenges for the acceptance of RWE

Dr Richard White
Oxford PharmaGenesis
Efficacy (RCT) vs effectiveness (RWE): An analogy

Standing quarter mile

12.5 seconds

Standing quarter mile

> 12.5 seconds!
External challenges for RWE – trust in the methodology, and trust in the pharma industry

Editorial

For reprint orders, please contact: reprints@futuremedicine.com

Building trust in real-world evidence and comparative effectiveness research: the need for transparency

“The demand for real-world evidence will continue to increase, but work needs to be done to break down the current barriers to acceptance of real-world evidence in influencing healthcare decision-making.”

First draft submitted: 7 October 2016; Accepted for publication: 10 October 2016; Published online: 19 October 2016

Keywords: observational • patient outcomes • policy • real-world data

Real-world evidence (RWE) – defined by the International Society for Pharmacoeconomics and Outcomes Research as “data used for clinical, coverage and payment decision-making that are not collected in conventional randomized controlled trials (RCTs)” [1] – is increasingly required by regulators, payers and CER studies in particular, are therefore at risk of significant bias if outcomes with different treatment options are compared without adjustment for confounders such as patient demographics, disease severity, comorbidities and concomitant medications. Selection bias is almost inevitable in RWE,
Challenge 1 – ‘You haven’t randomized, so you’re not comparing apples with apples’

Standing quarter mile
16.2 seconds

Standing quarter mile
21.6 seconds

Standing quarter mile
12.5 seconds
Challenge 2 – ‘Industry designs their studies to give them the results they want to see’

Standing quarter mile
19.5 seconds

Standing quarter mile
21.6 seconds
Challenge 3 – ‘Industry does lots of studies but only publishes the ones that give the best results’
External challenges for RWE: *Prescrire* comments on the HMA-EMA Joint Big Data Taskforce (1/2)

**Prescrire comments**

on the core recommendations of the summary report of the HMA-EMA Joint Big Data Taskforce

We would like to thank the HMA-EMA Joint Big Data Taskforce for having opened a public consultation on their summary report outlining a set of recommendations and associated actions on what needs to be addressed.

External challenges for RWE: *Prescrire* comments on the HMA-EMA Joint Big Data Taskforce (2/2)

- ‘We strongly invite EMA and HMA to consider very carefully the source and quality of “big data” and their internal validity and utility…’
- ‘We urge European and national regulators not to weaken marketing authorization requirements by shifting the provision of evidence to real world data…’
- ‘They should address the major methodological challenge of bias in real life data, that historically led to the development of RCT…’
- ‘Recommendations should be based on robust evidence generated through independent rigorous evaluation free from vested financial conflicts of interests’
Building trust in RWE: A task for all of us

‘With access to potentially life-enhancing new treatments at stake, we owe it to patients to act together to build trust in RWE through greater transparency.’
Thank you!